8.550USD-6.15%Mkt Cap: 684.92M USDP/E: —Last update: 2026-05-22
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase maligna…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap684.92M USD
Enterprise Value480.14M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-134.04M USD
Revenue/Share—
Last Price8.550 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees92
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.25
PEG—
EV/EBITDA-2.85
EV/Revenue—
P/S—
P/B1.96
EPS (TTM)-1.92
EPS (Forward)-2.14
52W Range
7.60013% of range14.87
52W High14.87 USD
52W Low7.600 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-32.61%
ROA-29.90%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-113.89M USD
CapEx (TTM)606.00K USD
FCF Margin—
FCF Yield-13.04%
Net Debt-249.63M USD
Net Debt/EBITDA1.48
Balance Sheet
Debt/Equity0.01
Current Ratio6.16
Quick Ratio5.83
Book Value/Sh4.648 USD
Cash/Share3.149 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)25.11 USD
Target Range18.00 USD – 41.00 USD
# Analysts9
Ownership
Shares Out.80.11M
Float35.71M
Insiders27.20%
Institutions68.86%
Short Interest
Short Ratio7.0d
Short % Float11.66%
Short % Out.4.14%
Shares Short3.32M
Short (prev mo.)2.39M
Technical
SMA 508.761 (-2.4%)
SMA 20010.73 (-20.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)488.35K
Avg Vol (10d)452.20K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—